Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA; Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA; Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Lancet Respir Med. 2020 Jul;8(7):696-708. doi: 10.1016/S2213-2600(20)30101-6.
Genetic factors influence chronic obstructive pulmonary disease (COPD) risk, but the individual variants that have been identified have small effects. We hypothesised that a polygenic risk score using additional variants would predict COPD and associated phenotypes.
We constructed a polygenic risk score using a genome-wide association study of lung function (FEV and FEV/forced vital capacity [FVC]) from the UK Biobank and SpiroMeta. We tested this polygenic risk score in nine cohorts of multiple ethnicities for an association with moderate-to-severe COPD (defined as FEV/FVC <0·7 and FEV <80% of predicted). Associations were tested using logistic regression models, adjusting for age, sex, height, smoking pack-years, and principal components of genetic ancestry. We assessed predictive performance of models by area under the curve. In a subset of studies, we also studied quantitative and qualitative CT imaging phenotypes that reflect parenchymal and airway pathology, and patterns of reduced lung growth.
The polygenic risk score was associated with COPD in European (odds ratio [OR] per SD 1·81 [95% CI 1·74-1·88] and non-European (1·42 [1·34-1·51]) populations. Compared with the first decile, the tenth decile of the polygenic risk score was associated with COPD, with an OR of 7·99 (6·56-9·72) in European ancestry and 4·83 (3·45-6·77) in non-European ancestry cohorts. The polygenic risk score was superior to previously described genetic risk scores and, when combined with clinical risk factors (ie, age, sex, and smoking pack-years), showed improved prediction for COPD compared with a model comprising clinical risk factors alone (AUC 0·80 [0·79-0·81] vs 0·76 [0·75-0·76]). The polygenic risk score was associated with CT imaging phenotypes, including wall area percent, quantitative and qualitative measures of emphysema, local histogram emphysema patterns, and destructive emphysema subtypes. The polygenic risk score was associated with a reduced lung growth pattern.
A risk score comprised of genetic variants can identify a small subset of individuals at markedly increased risk for moderate-to-severe COPD, emphysema subtypes associated with cigarette smoking, and patterns of reduced lung growth.
US National Institutes of Health, Wellcome Trust.
遗传因素会影响慢性阻塞性肺疾病(COPD)的风险,但已确定的个体变异仅具有较小的影响。我们假设,使用其他变体的多基因风险评分将预测 COPD 及其相关表型。
我们使用英国生物库和 SpiroMeta 的肺功能(FEV 和 FEV/FVC)全基因组关联研究构建了一个多基因风险评分。我们在多个种族的九个队列中测试了该多基因风险评分与中重度 COPD(定义为 FEV/FVC<0.7 和 FEV<80%预测值)的关联。使用逻辑回归模型测试关联,调整年龄、性别、身高、吸烟包年数和遗传祖先的主成分。我们通过曲线下面积评估模型的预测性能。在研究的一个子集,我们还研究了反映实质和气道病理以及减少的肺生长模式的定量和定性 CT 成像表型。
多基因风险评分与欧洲人群(SD 每增加一个单位的优势比[OR]为 1.81[95%CI 1.74-1.88])和非欧洲人群(1.42[1.34-1.51])的 COPD 相关。与第一十分位数相比,多基因风险评分的十分位数与 COPD 相关,在欧洲血统队列中 OR 为 7.99(6.56-9.72),在非欧洲血统队列中 OR 为 4.83(3.45-6.77)。多基因风险评分优于先前描述的遗传风险评分,当与临床危险因素(即年龄、性别和吸烟包年数)结合使用时,与仅包含临床危险因素的模型相比,改善了 COPD 的预测效果(AUC 为 0.80[0.79-0.81] 比 0.76[0.75-0.76])。多基因风险评分与 CT 成像表型相关,包括壁面积百分比、定量和定性肺气肿测量、局部直方图肺气肿模式和破坏性肺气肿亚型。多基因风险评分与肺生长模式减少相关。
由遗传变异组成的风险评分可以识别出一小部分 COPD 风险显著增加的个体、与吸烟相关的肺气肿亚型和肺生长减少的模式。
美国国立卫生研究院、惠康信托基金会。